The Cancer Research Society, in partnership with PROCURE, is offering a unique funding opportunity to support translational research in prostate cancer. Four grants of $500,000 each will be awarded to groundbreaking projects focused on early detection and treatment strategies.
Scope of Research:
-
Predictive biomarkers of disease progression or treatment response
-
Novel therapeutic strategies
-
Mechanisms of treatment resistance
-
Correlative studies using biospecimens from clinical trials or well-annotated cohorts
-
Projects must show feasibility within a 3-year term
Eligibility:
-
Principal Investigator must hold an academic appointment and independent lab at a Canadian institution
-
Co-applicants (max 3) must be based in Canada
-
Collaborators can be international but cannot receive funds
-
Early Career Investigators are encouraged to apply
-
Only one application per PI is permitted
Key Dates:
-
Letter of Intent Deadline: May 28, 2025
-
Notification of LOI Acceptance: June 12, 2025
-
Full Proposal Deadline: September 9, 2025
-
Funding Start Date: December 2025
Funding Details:
-
Total per grant: 500,000 CAD over 3 years
-
Funds must be spent in Canada
-
Covers staff, trainee stipends, research costs, biospecimen acquisition, patient engagement, and publication/travel costs
-
Does not cover PI/co-PI salaries, equipment, indirect costs, or new investigator relocation expenses
How to Apply:
-
LOI submission via CRS Portal (ProposalCentral)
-
Only approved LOIs may submit full proposals
-
A patient engagement plan is strongly encouraged
-
Inclusion of EDI principles and HTA considerations is expected